# A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

> **NCT07373613** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 330 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** BR1400-1
- **DRUG:** BR1400-2
- **DRUG:** BR1400-3
- **DRUG:** BR1400-4
- **DRUG:** BR1400-5
- **DRUG:** BR1400-A
- **DRUG:** BR1400-B
- **DRUG:** BR1400-C

## Key facts

- **NCT ID:** NCT07373613
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07373613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07373613, "A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07373613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*